Yuhei Okubo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuhei Okubo has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Iwao Fukui
Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
3 shared publications - Junji Yonese
Department of Genitourinary Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
3 shared publications - Yuichi Ishikawa
The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan
3 shared publications - Satoru Kawakami
Department of Urology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan
2 shared publications - Yoshinobu Komai
Department of Urology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan
2 shared publications Hideki Takeshita
Department of Urology, Cancer Institute Hospital and
1 shared publication
Latest Publications
- Open Access
- 8 September 2008
- Published by Wiley in International Journal of Urology
- Vol. 15 (9) , 851-853
Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus
- 8 September 2008
- Published by Wiley in International Journal of Urology
- Vol. 15 (9) , 851-853
Open AccessPreliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus
- Open Access
- 23 August 2007
- Published by Wiley in International Journal of Urology
- Vol. 14 (9) , 854-855
Obstinate cough as a sole presenting symptom of non‐metastatic renal cell carcinoma
Renal cell carcinoma (RCC) causes many kinds of symptoms such as hypercalcemia, hypertension, polycythemia and fever. Here we describe a rare case of RCC presenting with a persistent cough. After radical nephrectomy, the obstinate cough disappeared. When the tumor recurred locally, the cough also recurred. Furthermore, the cough disappeared completely again after the removal of the recurrent tumor. Although all the clinical findings suggested that the RCC caused the cough, we could not identify a specific humoral substance responsible for the cough.
- 23 August 2007
- Published by Wiley in International Journal of Urology
- Vol. 14 (9) , 854-855
Open AccessObstinate cough as a sole presenting symptom of non‐metastatic renal cell carcinoma
Renal cell carcinoma (RCC) causes many kinds of symptoms such as hypercalcemia, hypertension, polycythemia and fever. Here we describe a rare case of RCC presenting with a persistent cough. After radical nephrectomy, the obstinate cough disappeared. When the tumor recurred locally, the cough also recurred. Furthermore, the cough disappeared completely again after the removal of the recurrent tumor. Although all the clinical findings suggested that the RCC caused the cough, we could not identify a specific humoral substance responsible for the cough.
- 1 January 1995
- Published by Japanese Urological Association in The Japanese Journal of Urology
- Vol. 86 (12) , 1784-1788
PRIMARY RETROPERITONEAL PURE CHORIOCARCINOMA
A thirty-year-old clerk presented with a history of left supraclavicular lymph node swelling of a month duration and newly detected multiple lung and mediastinal tumors. Abdominal computed tomography showed two retroperitoneal masses, but no abnormality in both testes was found by physical and ultrasonographic examination. Biopsy of supraclavicular lymph nodes revealed pure choriocarcinoma. Furthermore, β-subunit of human chorionic gonadotropin was elevated up to 700ng/ml but alfafetoprotein was normal, resulting in the diagnosis of primary retroperitoneal pure choriocarcinoma. Two cycles of combination chemotherapy with etoposide (VP-16), ifosfamide and cisplatin (VIP) was given and followed by bleomycin, etoposide and cisplatin (BEP) (2 cycles) because of cystitis symptom due to ifosfamide. Since post chemotherapeutic evaluation revealed only partial response, we surgically removed all residual masses in the lung, mediastinum and retroperitoneum, which histologically proved to be necrotic fibrous tissue. He has remained disease-free 15 months after surgery without additional therapy.In order to improve prognosis of primary retroperitoneal pure choriocarcinoma, intense chemotherapeutic regimen like VIP should be given, regularly repeated and followed by aggressive surgical resection of residual masses.
- 1 January 1995
- Published by Japanese Urological Association in The Japanese Journal of Urology
- Vol. 86 (12) , 1784-1788
PRIMARY RETROPERITONEAL PURE CHORIOCARCINOMA
A thirty-year-old clerk presented with a history of left supraclavicular lymph node swelling of a month duration and newly detected multiple lung and mediastinal tumors. Abdominal computed tomography showed two retroperitoneal masses, but no abnormality in both testes was found by physical and ultrasonographic examination. Biopsy of supraclavicular lymph nodes revealed pure choriocarcinoma. Furthermore, β-subunit of human chorionic gonadotropin was elevated up to 700ng/ml but alfafetoprotein was normal, resulting in the diagnosis of primary retroperitoneal pure choriocarcinoma. Two cycles of combination chemotherapy with etoposide (VP-16), ifosfamide and cisplatin (VIP) was given and followed by bleomycin, etoposide and cisplatin (BEP) (2 cycles) because of cystitis symptom due to ifosfamide. Since post chemotherapeutic evaluation revealed only partial response, we surgically removed all residual masses in the lung, mediastinum and retroperitoneum, which histologically proved to be necrotic fibrous tissue. He has remained disease-free 15 months after surgery without additional therapy.In order to improve prognosis of primary retroperitoneal pure choriocarcinoma, intense chemotherapeutic regimen like VIP should be given, regularly repeated and followed by aggressive surgical resection of residual masses.